We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AMRI Completes Strategic European Acquisition

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "AMRI Completes Strategic European Acquisition"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Albany Molecular Research, Inc. has announced that it has completed the acquisition of ComGenex, located in Budapest, Hungary.

On January 30, AMRI announced the signing of a stock purchase agreement to acquire ComGenex. The completed acquisition provides AMRI with an immediate presence in Europe.

In combination with AMRI's facilities in the U.S. and Asia, the acquisition enhances the company's ability to offer a range of flexible services and cost models and provides a hub from which to establish additional relationships with European pharmaceutical and biotechnology companies.

"All of us at AMRI welcome ComGenex employees to our team. We look forward to achieving the synergies that can occur when two strong organizations combine resources," said AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D.